Eli Lilly to Invest $2.17 Billion in New German Plant

The pharmaceutical giant's investment, driven by surging demand for its diabetes drug Mounjaro, is expected to create over 1,000 jobs in the region.

Eli Lilly plans to invest 2 billion euros ($2.17 billion) in a new pharmaceutical production plant in Alzey, western Germany.
The project will be fully funded by Eli Lilly, in response to surging demand for its diabetes drug Mounjaro.
The new plant is expected to create more than 1,000 jobs, including a boost to sub-contractors and suppliers in the region.
Mounjaro, originally developed for diabetes, has been used off-label for weight loss and was recently cleared for that additional use in the United States under the new brand Zepbound.
The investment is seen as a win for the German government, which is keen to show that Europe's biggest economy remains an attractive manufacturing location despite soaring energy prices.